Zydus Lifesciences rises on signing co-marketing agreement with Guardant Health
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Zydus Lifesciences is currently trading at Rs. 577.30, up by 2.00 points or 0.35% from its previous closing of Rs. 575.30 on the BSE.
The scrip opened at Rs. 578.30 and has touched a high and low of Rs. 580.65 and Rs. 571.65 respectively. So far 3076 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 390.10 on 22-Nov-2022.
Last one week high and low of the scrip stood at Rs. 589.95 and Rs. 570.35 respectively. The current market cap of the company is Rs. 58540.83 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 17.95% and 7.07% respectively.
Zydus Lifesciences and Guardant Health, a leading precision oncology company, have signed a co-marketing agreement to jointly promote the Guardant360 portfolio of liquid and tissue biopsy tests across India and Nepal. The tests to be promoted include the Guardant360 and Guardant360 TissueNext tests for comprehensive genomic profiling and the Guardant360 Response test for monitoring response to treatment.
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region. By combining resources and expertise, both organisations aim to empower oncologists with the necessary tools to help inform treatment decisions for patients with advanced cancer.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
